At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
MiStent SESdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-In-Human Trial of a New Novel DES (MiStent System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries
In Brief
A Phase 2 clinical trial evaluating MiStent SES for Coronary Artery Disease. Completed, enrolled 30 participants across 5 sites in 3 countries.
Detailed Summary
The DESSOLVE I clinical trial is to assess the safety and performance of the sirolimus-eluting MiStent SES.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesAustralia, Belgium, New Zealand
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionSep 2012
Study CompletionMar 2016
TodayJul 2026
First PostedNov 24, 2010
Enrollment StartNov 1, 2010
Primary CompletionSep 1, 2012
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.6 years ago
Interventions
MiStent SESdevice
The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).